 Connection
Bradley Corr to Maytansine
This is a "connection" page, showing publications Bradley Corr has written about Maytansine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.293 |
|
|
|
-
Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barqu?n A, G?lvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Rubio P?rez MJ, Bonaventura A, Diver EJ, Ayuk SM, Wang Y, Corr BR, Salutari V. The efficacy and safety of mirvetuximab soravtansine in FRa-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Ann Oncol. 2025 Mar; 36(3):321-330.
Score: 0.233
-
Alqaisi HA, Cohn DE, Chern JY, Duska LR, Jewell A, Corr BR, Winer IS, Girda E, Crispens MA, Dhani NC, Madariaga A, Grant RC, Malaguti M, Lee C, Bowering V, Wong H, Poothullil A, Speers V, Wang L, Bedard PL, Brady JC, Nixon AB, Chen L, O'Connor C, Zamboni W, McKee T, Moscow JA, Oza AM, Lheureux S. Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). Clin Cancer Res. 2025 Mar 17; 31(6):993-1001.
Score: 0.059
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|